Table 1
Institutional protocol for VTE prophylaxis in patients undergoing THA based on risk stratification.
| Risk stratification | Regimen | Duration |
|---|---|---|
| Low-risk patients (planned for fast-track or outpatient THA) | Rivaroxaban 10 mg and aspirin 100 mg | Rivaroxaban 10 mg once daily for 5 days starting on POD 1 plus aspirin 100 mg once daily for 30 days |
| Intermediate-risk patients (older than 60 years old, bilateral THA, diabetic, greater than Class I heart failure, atrial fibrillation, or varicose veins) | Enoxaparin 40 mg + Dabigatran 220 mg/d (or 150 mg/d, adjusted for weight and renal function) | Enoxaparin 40 mg starting on POD 1, dabigatran 220 mg/d (or 150 mg/d adjusted for weight and renal function) for 30 days commencing upon discharge [38] |
| High-risk patients (history of VTE, active cancer, greater than Class I congestive heart failure or atrial fibrillation treated with anticoagulant, thrombophilia, prolonged immobility, BMI >40, steroid administration, hip fracture) | Enoxaparin 40 mg | Enoxaparin 40 mg once daily starting on POD 1 for 30 days. |
POD: Postoperative Day.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.